Harting J, et al. - Authors sought to describe their experience with the use of telavancin in patients with methicillin-resistant Staphylococcus aureus (MRSA) osteomyelitis and prosthetic joint infection. Findings suggested a role of telavancin in treatment of MRSA osteomyelitis and prosthetic joint infection. The study described clinical success and adverse events for long duration of therapy, up to eight weeks.